GE unveils CleaRecon DL for sharper CBCT images

USA – GE HealthCare has introduced CleaRecon DL, a new AI-powered deep learning solution designed to enhance the quality of cone-beam computed tomography (CBCT) images.

Now cleared by the FDA (510(k)) and awarded the CE mark, the technology will be integrated into GE’s Allia platform, bringing a new level of precision to interventional radiology.

CBCT plays a key role in interventional procedures by providing cross-sectional imaging during treatments.

However, image clarity often suffers due to artifacts caused by pulsatile blood flow and contrast distribution changes, particularly in procedures involving the liver, prostate, brain, and aorta.

These image distortions can reduce a clinician’s ability to accurately interpret scans, potentially affecting treatment decisions.

CleaRecon DL addresses these challenges by using deep learning algorithms to minimize streak artifacts and improve image detail.

In clinical validation testing, 98% of cases showed improved clarity over standard CBCT images, and 94% of clinicians reported higher confidence in interpreting the results.

“This technology marks a significant step forward for image-guided interventions,” said Arnaud Marie, General Manager of Interventional Solutions at GE HealthCare.

“By delivering clearer images with fewer artifacts, CleaRecon DL helps clinicians perform procedures with greater precision and improves workflow efficiency, ultimately supporting better outcomes for patients.”